Choate Investment Advisors Raised Its Biogen (BIIB) Position; Cadence Bank Na Has Cut Target (TGT) Holding by $1.12 Million

December 17, 2017 - By Richard Conner

Choate Investment Advisors increased its stake in Biogen Inc (BIIB) by 16.79% based on its latest 2017Q2 regulatory filing with the SEC. Choate Investment Advisors bought 312 shares as the company’s stock declined 13.45% while stock markets rallied. The institutional investor held 2,170 shares of the biological products (no diagnostic substances) company at the end of 2017Q2, valued at $588.85M, up from 1,858 at the end of the previous reported quarter. Choate Investment Advisors who had been investing in Biogen Inc for a number of months, seems to be bullish on the $69.35 billion market cap company. The stock increased 1.36% or $4.39 during the last trading session, reaching $327.94. About 2.02M shares traded or 63.02% up from the average. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since December 17, 2016 and is uptrending. It has underperformed by 11.76% the S&P500.

Cadence Bank Na decreased its stake in Target Corp (TGT) by 63.26% based on its latest 2017Q2 regulatory filing with the SEC. Cadence Bank Na sold 21,526 shares as the company’s stock declined 14.90% while stock markets rallied. The institutional investor held 12,501 shares of the department and specialty retail stores company at the end of 2017Q2, valued at $654,000, down from 34,027 at the end of the previous reported quarter. Cadence Bank Na who had been investing in Target Corp for a number of months, seems to be less bullish one the $34.03B market cap company. The stock increased 1.08% or $0.67 during the last trading session, reaching $62.61. About 9.15 million shares traded or 31.66% up from the average. Target Corporation (NYSE:TGT) has declined 16.51% since December 17, 2016 and is downtrending. It has underperformed by 33.21% the S&P500.

Investors sentiment decreased to 0.88 in 2017 Q2. Its down 0.16, from 1.04 in 2017Q1. It turned negative, as 81 investors sold BIIB shares while 321 reduced holdings. 78 funds opened positions while 277 raised stakes. 180.66 million shares or 1.01% less from 182.50 million shares in 2017Q1 were reported. Centurylink Invest Mngmt Company reported 5,620 shares. Plante Moran Fincl Advsr Limited Liability stated it has 0.05% in Biogen Inc. (NASDAQ:BIIB). Strategic Advsr Ltd Liability holds 0.18% or 1,848 shares. Gru One Trading Limited Partnership reported 3,969 shares or 0.01% of all its holdings. Prudential Financial Incorporated holds 688,495 shares or 0.28% of its portfolio. Neuberger Berman Grp Inc Ltd Llc reported 0.01% stake. Pinnacle Assoc invested 0.05% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Wfg Advsr Lp holds 590 shares or 0.04% of its portfolio. Jackson Square Prtnrs Limited Liability Corp stated it has 2.06M shares. Nine Masts Ltd invested 0.21% in Biogen Inc. (NASDAQ:BIIB). Pggm Investments invested in 103,980 shares or 0.14% of the stock. Peddock Cap Advsr Ltd Llc owns 0.34% invested in Biogen Inc. (NASDAQ:BIIB) for 2,326 shares. Essex Investment Ltd Com holds 28,442 shares or 1.1% of its portfolio. Charter Trust Co reported 1,912 shares. Westpac Banking reported 14,415 shares stake.

Among 31 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 21 have Buy rating, 0 Sell and 10 Hold. Therefore 68% are positive. Biogen Idec Inc. had 92 analyst reports since July 23, 2015 according to SRatingsIntel. Goldman Sachs upgraded the shares of BIIB in report on Wednesday, July 26 to “Buy” rating. The stock has “Buy” rating by Bank of America on Wednesday, October 18. The company was maintained on Monday, July 27 by Argus Research. On Monday, November 27 the stock rating was maintained by BMO Capital Markets with “Buy”. The company was maintained on Tuesday, October 24 by Goldman Sachs. Nomura maintained Biogen Inc. (NASDAQ:BIIB) on Friday, July 14 with “Buy” rating. The firm has “Buy” rating by Standpoint Research given on Thursday, January 7. The firm has “Equal-Weight” rating given on Thursday, March 16 by Morgan Stanley. The stock of Biogen Inc. (NASDAQ:BIIB) has “Strong Buy” rating given on Thursday, December 29 by Raymond James. The stock has “Hold” rating by BMO Capital Markets on Monday, July 17.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: